» Articles » PMID: 27194212

Primary Hyperparathyroidism

Overview
Specialty General Medicine
Date 2016 May 20
PMID 27194212
Citations 87
Authors
Affiliations
Soon will be listed here.
Abstract

Primary hyperparathyroidism (PHPT) is a common disorder in which parathyroid hormone (PTH) is excessively secreted from one or more of the four parathyroid glands. A single benign parathyroid adenoma is the cause in most people. However, multiglandular disease is not rare and is typically seen in familial PHPT syndromes. The genetics of PHPT is usually monoclonal when a single gland is involved and polyclonal when multiglandular disease is present. The genes that have been implicated in PHPT include proto-oncogenes and tumour-suppressor genes. Hypercalcaemia is the biochemical hallmark of PHPT. Usually, the concentration of PTH is frankly increased but can remain within the normal range, which is abnormal in the setting of hypercalcaemia. Normocalcaemic PHPT, a variant in which the serum calcium level is persistently normal but PTH levels are increased in the absence of an obvious inciting stimulus, is now recognized. The clinical presentation of PHPT varies from asymptomatic disease (seen in countries where biochemical screening is routine) to classic symptomatic disease in which renal and/or skeletal complications are observed. Management guidelines have recently been revised to help the clinician to decide on the merits of a parathyroidectomy or a non-surgical course. This Primer covers these areas with particular attention to the epidemiology, clinical presentations, genetics, evaluation and guidelines for the management of PHPT.

Citing Articles

Calcium to magnesium ratio as a superior biomarker for nephrolithiasis detection in primary hyperparathyroidism.

Yalcin N, Ertinmaz Ozkan A, Gunes E, Koca N Sci Rep. 2025; 15(1):3545.

PMID: 39875421 PMC: 11775213. DOI: 10.1038/s41598-025-86954-4.


[Significance and methodology of monitoring calcemia in disorders of mineral metabolism: challenges and prospects].

Chubakova K, Kamenskih E, Saprina T Probl Endokrinol (Mosk). 2025; 70(6):83-90.

PMID: 39868450 PMC: 11775675. DOI: 10.14341/probl13413.


Progress report on multiple endocrine neoplasia type 1.

Halperin R, Tirosh A Fam Cancer. 2025; 24(1):15.

PMID: 39826015 PMC: 11742904. DOI: 10.1007/s10689-025-00440-4.


Near-Infrared Autofluorescence or Intraoperative Parathyroid Hormone Determination as a Surgical Support Tool in Primary Hyperparathyroidism: Too Close to Call?.

Indelicato P, Barbieri D, Salerno E, Tettamanti A, Guizzardi M, Galli A Cancers (Basel). 2024; 16(23).

PMID: 39682204 PMC: 11640253. DOI: 10.3390/cancers16234018.


Association between atopic dermatitis with hyperparathyroidism not mediated by vitamin D in the United States (NHANES 2005-2006).

Xu L, Cao Y Arch Dermatol Res. 2024; 317(1):100.

PMID: 39666073 DOI: 10.1007/s00403-024-03609-6.


References
1.
Starup-Linde J, Waldhauer E, Rolighed L, Mosekilde L, Vestergaard P . Renal stones and calcifications in patients with primary hyperparathyroidism: associations with biochemical variables. Eur J Endocrinol. 2012; 166(6):1093-100. DOI: 10.1530/EJE-12-0032. View

2.
Pradeep P, Jayashree B, Mishra A, Mishra S . Systematic review of primary hyperparathyroidism in India: the past, present, and the future trends. Int J Endocrinol. 2011; 2011:921814. PMC: 3124672. DOI: 10.1155/2011/921814. View

3.
Bess M, Edis A, Van Heerden J . Hyperparathyroidism and pancreatitis. Chance or a causal association?. JAMA. 1980; 243(3):246-7. View

4.
Cesareo R, Di Stasio E, Vescini F, Campagna G, Cianni R, Pasqualini V . Effects of alendronate and vitamin D in patients with normocalcemic primary hyperparathyroidism. Osteoporos Int. 2014; 26(4):1295-302. DOI: 10.1007/s00198-014-3000-2. View

5.
Webb S, Puig-Domingo M, Villabona C, Munoz-Torres M, Farrerons J, Badia X . Development of a new tool for assessing health-related quality of life in patients with primary hyperparathyroidism. Health Qual Life Outcomes. 2013; 11:97. PMC: 3710251. DOI: 10.1186/1477-7525-11-97. View